Document is current

Article History

Received: 28 September 2022

Accepted: 5 July 2023

First Online: 21 July 2023

Declarations

:

: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

: KMS reports honoraria for speaking and/or advisory boards from Sanofi and Takeda. AB has received consulting fees from Sanofi and Takeda. PBD has received consulting fees from Sanofi. DH has received honoraria for speaking and advisory boards, administered through UCL consultants, from Sanofi, Takeda, amicus, Freeline, Idorsia and Chiesi. AJ has received honoraria for participating in advisory boards for Sanofi, Amicus Therapeutics, Chiesi and Takeda, and research grant support from Amicus Therapeutics. LM has received honoraria as a speaker and educational support from Amicus, Sanofi and Takeda. AM has received honoraria and travel subsidence for participation in advisory panels for Amicus and Sanofi. UR has received honoraria for speaking or advisory boards from Amicus, Sanofi, Takeda and research grants from Amicus, Intrabio and Takeda. UR and AB participated in the advisory board meeting in 2021 run by Sanofi – “Understanding how Fabry disease is managed in children in the current UK and Ireland clinical practice”. Both report consultancy fees for this activity.

: Editorial assistance in the preparation of this manuscript was provided by Dr Robert Brines of Bite Medical Consulting. Funding for writing support was provided by Sanofi.

: Not applicable.

: Not applicable.